Idioma:

Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial

Viale, G. ; de Snoo, F. A. ; Slaets, L. ; Bogaerts, J. ; van ’t Veer, L. ; Rutgers, E. J. ; Piccart-Gebhart, M. J. ; Stork-Sloots, L. ; Glas, A. ; Russo, L. ; Dell’Orto, P. ; Tryfonidis, K. ; Litière, S. ; Cardoso, F.

Breast cancer research and treatment, 2018, Vol.167 (1), p.123-131 [Periódico revisado por pares]

New York: Springer US

Texto completo disponível

Citações Citado por

Enviar para

Título:
Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial
Autor: Viale, G. ; de Snoo, F. A. ; Slaets, L. ; Bogaerts, J. ; van ’t Veer, L. ; Rutgers, E. J. ; Piccart-Gebhart, M. J. ; Stork-Sloots, L. ; Glas, A. ; Russo, L. ; Dell’Orto, P. ; Tryfonidis, K. ; Litière, S. ; Cardoso, F.
Assuntos: Adjuvant chemotherapy ; Adjuvant treatment ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biomarkers, Tumor - genetics ; Breast cancer ; Breast carcinoma ; Breast Neoplasms - drug therapy ; Breast Neoplasms - epidemiology ; Breast Neoplasms - genetics ; Breast Neoplasms - pathology ; Cancer ; Cancer metastasis ; Cancer research ; Cancer therapies ; Chemotherapy ; Classification ; Clinical medicine ; Clinical Trial ; Disease-Free Survival ; Endocrine therapy ; ErbB-2 protein ; Female ; Gene expression ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic ; Humans ; In Situ Hybridization, Fluorescence ; Ki-67 Antigen - genetics ; Laboratories ; Medicine ; Medicine & Public Health ; Metastases ; Metastasis ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Metastasis ; Neoplasm Proteins - genetics ; Oncology ; Pathology ; Patient outcomes ; Prognosis ; Proportional Hazards Models ; Receptors, Estrogen - genetics ; Receptors, Progesterone - genetics ; Tumors
É parte de: Breast cancer research and treatment, 2018, Vol.167 (1), p.123-131
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
Descrição: Purpose This study compares immunohistochemical (IHC) versus molecular subtyping (BluePrint and MammaPrint) in the population of patients enrolled in MINDACT and outcome based on molecular subtyping (MS) versus surrogate pathological subtyping (PS) as defined by the 2013 St. Gallen guidelines. Methods MS classified patients in the following subtypes: Luminal A, Luminal B, HER-2-, and Basal-type. IHC/FISH for pathological subtyping (ER, PgR, HER-2, and Ki67) was centrally assessed in the European Institute of Oncology ( n = 5806). Hazard ratios for distant-metastasis-free survival (DMFS) by subtype were adjusted for chemotherapy and endocrine therapy administration and thus independent of adjuvant treatment allocation. Results PS Luminal cancers classified as HER-2+ or Basal-type by MS did not have a significantly lower DMFS than the Luminal-type cancers by MS (95.9%): HR = 1.40, 95% CI 0.75–2.60 ( p = 0.294). More patients were identified with Luminal A disease by MS (63%) as compared with PS (47%) with comparable 5-year DMFS (≥96.0%). Among the 500 patients with PS TN cancers, MS identified 24 (5%) patients as Luminal-type with 5-year DMFS estimated at 100% versus 71.4% for MS HER-2+ or 90.1% for MS Basal-type. Conclusions MS was able to re-stratify 54% of patients with a Luminal-B PS subtype to a low-risk Luminal A-type group with comparable outcome. Among TN EBC, 5% were classified as Luminal by MS with Luminal-like outcome. Molecular classification can help to identify a larger group of patients with low risk of recurrence compared with the more contemporarily used classification methodology including high-quality assessed Ki67.
Editor: New York: Springer US
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial

Viale, G. ; de Snoo, F. A. ; Slaets, L. ; Bogaerts, J. ; van ’t Veer, L. ; Rutgers, E. J. ; Piccart-Gebhart, M. J. ; Stork-Sloots, L. ; Glas, A. ; Russo, L. ; Dell’Orto, P. ; Tryfonidis, K. ; Litière, S. ; Cardoso, F.

New York: Springer US

Buscando em bases de dados remotas. Favor aguardar.